(ZGNX - Get Report)
This is a specialty pharmaceutical company with two product candidates in late-stage development for the treatment of central nervous system disorders and pain. This stock is up 10.2% to $2.05 in recent trading.
Today's Range: $1.87-$2.08
52-week Range: $1.31-$5.11
Three-Month Average Volume: 305,806
Shares of ZGNX are soaring today after the company said Mallinckrodt LLC, the pharmaceuticals business of
, announced an exclusive co-promotion agreement for SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System in the United States.
From a technical perspective, ZGNX is bouncing right off its 50-day moving average here with above-average volume. This move is quickly pushing ZGNX within range of triggering a major breakout trade. That trade will hit once ZGNX takes out its 200-day moving average of $2.15, and then some past overhead resistance at $2.28 with high volume.
Traders should now look for long-biased trades, if ZGNX can sustain a move or close above those levels with volume that's near or above 305,806 shares. If we get that action soon, then look for ZGNX to fill a previous gap down and possibly hit its March high of $2.90.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts